Innovent Reports NMPA’s Acceptance of sNDA for Sintilimab as 1L Treatment for Esophageal Squamous Cell Carcinoma

 Innovent Reports NMPA’s Acceptance of sNDA for Sintilimab as 1L Treatment for Esophageal Squamous Cell Carcinoma

Innovent Signs a License Agreement with Union to Develop & Commercialize Orismilast for Inflammatory Dermatology Conditions in China

Shots:

  • The sNDA is based on the P-III ORIENT-15 clinical trial evaluates sintilimab + CT vs PBO + CT in a ratio (1:1) in 659 patients unresectable LA, recurrent or metastatic ESCC
  • In an interim analysis, the therapy demonstrated an improvement in the 1EPs of OS & PFS. The results were presented at ESMO 2021
  • Sintilimab is an innovative PD-1 inhibitor, jointly developed by Eli Lilly and Innovent. Additionally, Innovent has two regulatory submissions under review in China for sintilimab as 1L or 2L treatment of ESCC & NSCLC & is currently conducting 20+ clinical studies of sintilimab for multiple cancer

Click here to­ read full press release/ article | Ref: PR Newswire | Image: Innovent

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post